Myelodysplastic Syndrome (MDS) Drugs - Global Market Trajectory & Analytics

Global Myelodysplastic Syndrome (MDS) Drugs Market to Reach $3.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Myelodysplastic Syndrome (MDS) Drugs estimated at US$1.8 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 8.4% over the analysis period 2020-2027. Immunomodulatory Drugs, one of the segments analyzed in the report, is projected to record a 8.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Hypomethylating Agents segment is readjusted to a revised 5% CAGR for the next 7-year period.





The U.S. Market is Estimated at $491.6 Million, While China is Forecast to Grow at 12.9% CAGR

The Myelodysplastic Syndrome (MDS) Drugs market in the U.S. is estimated at US$491.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$743 Million by the year 2027 trailing a CAGR of 12.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.5% and 7.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Other Therapeutic Classes Segment to Record 13.5% CAGR

In the global Other Therapeutic Classes segment, USA, Canada, Japan, China and Europe will drive the 12.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$156.5 Million in the year 2020 will reach a projected size of US$361.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$447.5 Million by the year 2027, while Latin America will expand at a 15.5% CAGR through the analysis period.

Select Competitors (Total 34 Featured):

• Amgen
• BluePoint Laboratories
• Celgene Corporation
• Celgene Europe Limited
• Johnson & Johnson
• Lupin Ltd Corporation
• Otsuka America Pharmaceutical Inc.
• Reddy's Laboratories, Inc.
• Sandoz
• Shilpa Medicare Limited
• Sun Pharmaceutical Industries Inc.
• Takeda